Evaluation of the mRECIST and a-Fetoprotein Ratio for Stratification of the Prognosis of Advanced-Hepatocellular-Carcinoma Patients Treated with Sorafenib

Alpha-fetoprotein response correlates with EASL response and survival in solitary hepatocellular carcinoma treated with transarterial therapies: A subgroup analysis

(2012) Khairuddin Memon et al.   JOURNAL OF HEPATOLOGY

Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma

(2011) Julien Edeline et al.   CANCER

Des-γ-Carboxyprothrombin May Be a Promising Biomarker to Determine the Therapeutic Efficacy of Sorafenib for Hepatocellular Carcinoma

(2011) Kazuomi Ueshima et al.   DIGESTIVE DISEASES

Tumor Marker Levels Before and After Curative Treatment of Hepatocellular Carcinoma as Predictors of Patient Survival

(2011) Atsushi Nanashima et al.   DIGESTIVE DISEASES AND SCIENCES

The Significance of Early Alpha-Fetoprotein Level Changes in Predicting Clinical and Survival Benefits in Advanced Hepatocellular Carcinoma Patients Receiving Sorafenib

(2011) T. Yau et al.   ONCOLOGIST

Early Decrease in α-Fetoprotein, but Not Des-γ-Carboxy Prothrombin, Predicts Sorafenib Efficacy in Patients with Advanced Hepatocellular Carcinoma

(2011) Teiji Kuzuya et al.   ONCOLOGY

Favorable α-fetoprotein decrease as a prognostic surrogate in patients with hepatocellular carcinoma after radiofrequency ablation

(2010) Ming-Chao Tsai et al.   JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY

Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma

(2010) Riccardo Lencioni et al.   SEMINARS IN LIVER DISEASE

Cytoskeletal changes during epithelial-to-fibroblastoid conversion as a crucial mechanism of des-γ-carboxy prothrombin production in hepatocellular carcinoma

(2009) Murata   INTERNATIONAL JOURNAL OF ONCOLOGY

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER

New Utility of an Old Marker: Serial α-Fetoprotein Measurement in Predicting Radiologic Response and Survival of Patients With Hepatocellular Carcinoma Undergoing Systemic Chemotherapy

(2008) Stephen L. Chan et al.   JOURNAL OF CLINICAL ONCOLOGY

Design and Endpoints of Clinical Trials in Hepatocellular Carcinoma

(2008) Josep M. Llovet et al.   JNCI-Journal of the National Cancer Institute

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

(2008) Ann-Lii Cheng et al.   LANCET ONCOLOGY

Sorafenib in Advanced Hepatocellular Carcinoma

(2008) Josep M. Llovet et al.   NEW ENGLAND JOURNAL OF MEDICINE